medigraphic.com
Instituto Nacional de Salud Pública

2003, Número S3

<< Anterior Siguiente >>

salud publica mex 2003; 45 (S3)


Vacunas contra el virus del papiloma humano y cáncer cervical invasor

Lina VL

Idioma: Ingles.
Referencias bibliográficas: 69
Paginas: 443-448
Archivo PDF: 88.10 Kb.


RESUMEN

El cáncer de células escamosas del cérvix uterino es la segunda causa de muerte relacionada con cáncer en mujeres en el mundo; la incidencia más alta se ha observado en países en desarrollo. La infección con tipos oncogénicos de virus de papiloma humano es considerado el factor de riesgo principal para el desarrollo de malignidad en el cérvix uterino. Sin embargo, el virus es considerado una causa necesaria pero no suficiente para desarrollo de cáncer cervical y, por lo tanto, existen otros factores en el ambiente y en el huésped que contribuyen al proceso carcinogénico. Estudios desarrollados en animales, y más recientemente en humanos, indican que la vacunación en contra de la cápside de las proteínas del virus puede prevenir eficientemente la infección en forma profiláctica; además, las vacunas terapéuticas están bajo investigación con el propósito de promover regresión de los tumores inducidos por virus de papiloma humano. Las bases científicas de las vacunas desarrolladas contra este virus, y el estado actual de los ensayos clínicos que se desarrollan en el ámbito mundial, se presentan en este artículo.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bosch FX, Lörincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-265.

  2. Muñoz N, Bosch FX, De Sanjosé S, Herrero R, Castellsague X, Shah KV et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527.

  3. zur Hausen H. Immortalization of human cells and their malignant conversion by high risk papillomavirus genotypes. Sem Cancer Biol 1999;9:405-411.

  4. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res 2002;89(2):213-228.

  5. Bosch X. Epidemiology of human papillomavirus infections: New options for cervicakl prevention. Salud Publica Mex 2003;supl. 2:201-214.

  6. Frazer IH, Thomas R, Zhou J, Leggatt GR, Dunn L, McMillan N et al. Potential strategies utilised by papillomavirus to evade host immunity. Immunol Rev 1999;168:131-142.

  7. Konya J, Dillner J. Immunity to oncogenic human papillomaviruses. Advances Cancer Res 2001:205-238.

  8. Strickler HD, Schiffman MH, Shah KV, Rabkin CS, Schiller JT, Wacholder S et al. A survey of human papillomavirus 16 antibodies in patients with epithelial cancers. Eur J Cancer Prev 1998;7(4):305-313.

  9. Combita AL, Bravo MM, Touzé AA, Orozco O, Coursaget P. Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in colombian women with invasive cervical cancer. Int J Cancer 2002;97:796-803.

  10. Giroglou T, Sapp M, Lane C, Fligge C, Christensen ND, Streeck R et al. Immunological analyses of human papillomavirus capsids. Vaccine 2001;19:1783-1793.

  11. Pastrana D, Vass WC, Lowy DR, Schiller JT. NHPV 16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV 16. Virology 2001; 279:361-369.

  12. Schiller JT, Roden RBS. Papillomavirus-like particles. Papillomavirus Rep 1995;6:121-128.

  13. Lenz P, Day PM, Pang YY, Frye SA, Jensen PN, Lowy DR et al. Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol 2001;166(9):5346-5355.

  14. Rudolf MP, Fausch SC, Da Silva DM, Kast WM. Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J Immunol 2001;166(10):5917-5924.

  15. Breitburd F, Coursaget P. Human papillomavirus vaccines. Semin Cancer Biol 1999;9(6):431-444.

  16. Muller M, Zhou JA, Reed TD, Rittmuller C, Burger A, Gabelsberger J et al. Chimeric papillomavirus particles. Virology 1997;234:93-111.

  17. Greenstone HL, Nieland JD, de Visser KE, de Bruijn MLH, Kirnbauer R, Roden RBS et al. Chimeric papillomavirus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV 16 tumor model. Proc Natl Acad Sci 1998;95:1800-1805.

  18. Chen CH, Wu TC. Experimental vaccine strategies for cancer immunotherapy. J Biomed Sci 1998;5(4):231-252.

  19. Campo MS. Animal models of papillomavirus pathogenesis. Virus Res 2002;89(2):249-261.

  20. Schiller J, Lowy D. Papillomavirus-like particle based vaccines: Cervical cancer and beyond. Expert Opin Biol Ther 2001;1(4):571-581.

  21. Nicholls PK, Klaunberg BA, Moore RA, Santos EB, Parry NR, Stanley MA. Naturally-occurring, non-regressing canine oral papillomavirus infection: Host immunity, virus characterisation and experimental infection. Virology 1999;265:365-374.

  22. Peh WL, Middleton K, Christensen N, Nicholls P, Egawa K, Sotlar K et al. Life cycle heterogeneity in animal models of human papillomavirus-associated disease. J Virol 2002;76(20):10401-10416.

  23. Jansen KU, Rosolowsky M, Schultz L, Markus H, Cook JZ, Donnelly JJ et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits form CRPV-induced papilloma formation. Vaccine 1995;13:1509-1514.

  24. Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW. Immunization with virus-like particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 1996;70:960-965.

  25. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995;92:11553-11557.

  26. Tobery TW, Smith JF, Kuklin N, Skulsky D, Ackerson C, Huang L et al. Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized Rhesus macaques. Vaccine 2003;21(13-14):1539-1547.

  27. Dale CJ, Liu XS, De Rose R, Purcell DF, Anderson J, Xu Y et al. Chimeric human papilloma virus-simian/human immunodeficiency virus virus-like-particle vaccines: immunogenicity and protective efficacy in macaques.Virology 2002;301(1):176-187.

  28. Kast WM, Feltkamp MCW, Ressing ME, Vierboom MPM, Brandt RMP, Melief CJM. Cellular immunity against human papillomavirus associated cervical cancer. Sem Virol 1996;7:117-123.

  29. Gerard CM, Baudson N, Kraemer K, Bruck C, Garcon N, Paterson Y et al. Therapeutic potential of protein and adjuvant vaccinations on tumour growth. Vaccine 2001;19(17-19):2583-2589.

  30. Chu NR, Wu HB, Wu T, Boux LJ, Siegel MI, Mizzen LA. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacilli Calmette-Guérin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol 2000;121(2):216-225.

  31. Jabbar IA, Fernando GJ, Saunders N, Aldovini A, Young R, Malcolm K et al. Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins. Vaccine 2000;18(22):2444-2453.

  32. Chang EY, Chen CH, Ji H, Wang TL, Hung K, Lee BP et al. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. Int J Cancer 2000;86(5):725-730.

  33. Greer CE, Petracca R, Buonamassa DT, Di Tommaso A, Gervase B, Reeve RL et al. The comparison of the effect of LTR72 and MF59 adjuvants on mouse humoral response to intranasal immunisation with human papillomavirus type 6b (HPV-6b) virus-like particles. Vaccine 2000;19(9-10):1008-1012.

  34. Revaz V, Benyacoub J, Kast WM, Schiller JT, De Grandi P, Nardelli-Haefliger D. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice. Virology 2001;279(1):354-360.

  35. Gerber S, Lane C, Brown DM, Lord E, DiLorenzo M, Clements JD et al. Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. J Virol 2001;75(10):4752-4760.

  36. Ohlschlager P, Osen W, Dell K, Faath S, Garcea RL, Jochmus I et al. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.J Virol 2003;77(8):4635-4645.

  37. Yuan H, Estes PA, Chen Y, Newsome J, Olcese VA, Garcea RL et al. Immunization with a pentameric L1 fusion protein protects against papillomavirus infection. J Virol 2001;75(17):7848-7853.

  38. Chen CH, Ji H, Suh KW, Choti MA, Pardoll DM, Wu TC. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. Gene Ther 1999;6(12):1972-1981.

  39. Ji H, Wang TL, Chen CH, Pai SI, Hung CF, Lin KY et al. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther 1999;10(17):2727-2740.

  40. Smahel M, Sima P, Ludvikova V, Vonka V. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 2001;281(2):231-238.

  41. Rocha-Zavaleta L, Alejandre JE, García-Carrancá A. Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses. J Med Virol 2002;66(1):86-95.

  42. Schreckenberger C, Sethupathi P, Kanjanahaluethai A, Muller M, Zhou J, Gissmann L et al. Induction of an HPV 6bL1-specific mucosal IgA response by DNA immunization. Vaccine 2000;19(2-3):227-233.

  43. Leachman SA, Shylankevich M, Slade MD, Levine D, Sundaram RK, Xiao W et al. Ubiquitin-fused and/or multiple early genes from cottontail rabbit papillomavirus as DNA vaccines. J Virol 2002;76(15):7616-7624.

  44. Perrin P, Jacob Y, Aguilar-Setien A, Loza-Rubio E, Jallet C, Desmezieres E et al. Immunization of dogs with a DNA vaccine induces protection against rabies virus.Vaccine 1999;1418(5-6):479-486.

  45. Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA et al. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis 2001;183(10):1485-1493.

  46. Emeny RT, Wheeler CM, Jansen KU, Hunt WC, Fu TM, Smith JF et al. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J Virol 2002;76(15):7832-7842.

  47. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001;93(4):284-292.

  48. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB et al. A controlled trial of a human papillomavirus type 16 vaccine.N Engl J Med 2002;347(21):1645-1651.

  49. Villa LL, Costa R, Petta C, Andrade R, Ault K, Giuliano A et al. A dose ranging safety and immunogenicity study of a quadrivalent hpv (types 6/11/16/18) L1 VLP vaccine in women. Abstract presented at the XX International Papillomavirus Conference, Paris 2002, October 4-9; Paris, France.

  50. Frazer I. Vaccines for papillomavirus infection. Virus Res 2002;89(2):271-274.

  51. Stanley MA. Prognostic factors and new therapeutic approaches to cervical cancer. Virus Res 2002;89(2):241-248.

  52. Berry JM, Palefsky JM. A review of human papillomavirus vaccines: From basic science to clinical trials. Front Biosci 2003;8:333-345.

  53. Adams M, Borysiewicz L, Fiander A, Man S, Jasani B, Navabi H et al. Clinical studies of human papilloma vaccines in cervical cancer. Adv Exp Med Biol 2001;495:419-427.

  54. Ressing ME, van Driel WJ, Brandt RM, Kenter GG, de Jong JH, Bauknecht T et al. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 2000;23(2):255-266.

  55. Kaufmann AM, Nieland J, Schinz M, Nonn M, Gabelsberger J, Meissner H et al. HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination. Int J Cancer 2001;92(2):285-293.

  56. Zwaveling S, Ferreira-Mota SC, Nouta J, Johnson M, Lipford GB, Offringa R et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002;169(1):350-358.

  57. Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000;6(9):3406-3416.

  58. Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res 2002;8(12):3676-3685.

  59. Lacey CJ, Thompson HS, Monteiro EF, O’Neill T, Davies ML, Holding FP et al.Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J Infect Dis 1999;179(3):612-618.

  60. Zhang LF, Zhou J, Chen S, Cai LL, Bao QY, Zheng FY et al. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine 2000;18(11-12):1051-1058.

  61. Klencke B, Matijevic M, Urban RG, Lathey JL, Hedley ML, Berry M et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res 2002;8(5):1028-1037.

  62. De Bruijn ML, Schuurhuis DH, Vierboom MP, Vermeulen H, de Cock KA, Ooms ME et al. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res 1998;15;58(4):724-731.

  63. Wang TL, Ling M, Shih IM, Pham T, Pai SI, Lu Z et al. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther 2000;7(9):726-733.

  64. Mendoza L, Bubenik J, Simova J, Jandlova T, Vonka V, Mikyskova R. Prophylactic, therapeutic and anti-metastatic effects of BMDC and DC lines in mice carrying HPV 16-associated tumours. Int J Oncol 2003;23(1):243-247.

  65. Halpern AL. Comparison of papillomavirus and immunodeficiency virus evolutionary patterns in the context of a papillomavirus vaccine. J Clin Virol 2000;19(1-2):43-56.

  66. Goldie SJ. Health economics and cervical cancer prevention: A global perspective. Virus Res 2002;89(2):301-309.

  67. Plummer M, Franceschi S. Strategies for HPV prevention. Virus Res 2002;89(2):285-293.

  68. Hughes JP, Garnett GP, Koustky L. The theoretical population-level impact of a prophylactic human papillomavirus vaccine. Epidemiology 2002;13(6):631-639.

  69. Franconi R, Di Bonito P, Dibello F, Accardi L, Muller A, Cirilli A et al. Plant-derived human papillomavirus 16 E7 oncoprotein induces immune response and specific tumor protection. Cancer Res 2002;62(13): 3654-3658.




2020     |     www.medigraphic.com